ImmuCell

ImmuCell Current Assets

The Current Assets of ImmuCell (ICCC) as of Sep 29, 2026 is 13.53 M USD. In the previous year, Current Assets was 15.04 M USD — a change of -10.08% (lower).

Current Assets

13.53 MUSD

YoY

-10.08%

Last updated:

Current Assets of ImmuCell is 2026 13.53 M USD. Current Assets of ImmuCell was 2025 15.04 M USD. It decreases by -10.08% lower compared to the previous year.

The ImmuCell Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
5.93 M USD
Jan 1, 2019
13.19 M USD
Jan 1, 2020
12.15 M USD
Jan 1, 2021
16.26 M USD
Jan 1, 2022
13.99 M USD
Jan 1, 2023
11.51 M USD
Jan 1, 2024
15.04 M USD
Jan 1, 2025
13.53 M USD
The ImmuCell Current Assets history
YEARCurrent AssetsYoY
13.53 MUSD-10.08%
15.04 MUSD+30.70%
11.51 MUSD-17.76%
13.99 MUSD-13.95%
16.26 MUSD+33.83%
12.15 MUSD-7.88%
13.19 MUSD+122.63%
5.93 MUSD-19.43%
7.35 MUSD-48.22%
14.20 MUSD+81.15%
7.84 MUSD+43.22%
5.47 MUSD-24.51%
7.25 MUSD-1.09%
7.33 MUSD+2.57%
7.15 MUSD+2.56%
6.97 MUSD+10.41%
6.31 MUSD-6.15%
6.72 MUSD-4.82%
7.07 MUSD-15.39%
8.35 MUSD+22.95%
6.79 MUSD+16.73%
5.82 MUSD+8.11%
5.38 MUSD+19.81%
4.49 MUSD+28.23%
3.50 MUSD+3.33%
3.39 MUSD+20.12%
2.82 MUSD+20.09%
2.35 MUSD+7.80%
2.18 MUSD+5.31%
2.07 MUSD-19.14%
2.56 MUSD+11.30%
2.30 MUSD-19.30%
2.85 MUSD+33.80%
2.13 MUSD+21.71%
1.75 MUSD-42.24%
3.03 MUSD-15.13%
3.57 MUSD-23.06%
4.64 MUSD—
Access this data via the Eulerpool API

ImmuCell Stock analysis

What does ImmuCell do? ImmuCell Corp is an American company that specializes in the development and marketing of veterinary products for the ruminant industry. It was originally founded in the late 1970s under the name PrioGene and initially focused on the development of diagnostics for tuberculosis and brucellosis in cattle. In the 1990s, the company changed its name to ImmuCell and shifted its focus to the development of products to support animal health. ImmuCell's business model is centered around the development, manufacturing, and sale of products to improve animal health. They offer a wide range of veterinary products, including immunoassays, vaccines, antibiotics, and complementary feeds. The company aims to improve animal health with minimal impact on the environment and works closely with veterinarians and industry experts. They have divisions dedicated to diagnostics, vaccines, and antibiotics, and their products can help identify and prevent diseases in livestock. Notable products include the LBC mastitis diagnostic and the Immu-PRIME spray for preventing umbilical infections in newborn calves. ImmuCell has established itself as a leading innovator in the animal health industry and has conducted clinical studies on the efficacy of their HO-VAX product. In conclusion, ImmuCell focuses on developing and marketing products to support animal health, with a commitment to improving the well-being of livestock. ImmuCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImmuCell stock

Current Assets of ImmuCell is 13.53 M USD in 2026.

Current Assets of ImmuCell changed from 15.04 M USD to 13.53 M USD, representing a -10.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets ImmuCell since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's ImmuCell historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — ImmuCell

All Key Metrics — ImmuCell